AB Science SA (id:10785 AB)
0.795 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 11/27/2024 5:32:57 PM)
Exchange closed, opens in 15 hours 27 minutes
About AB Science SA
Market Capitalization 56.84M
AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
| Headquarters (address) |
3, avenue George V Paris 75008 France |
| Phone | 33 1 47 20 00 14 |
| Website | https://www.ab-science.com |
| Employees | 40 |
| Sector | Healthcare |
| Industry | Drug Manufacturers Specialty & Generic |
| Ticker | AB |
| Exchange | European Stock Exchange |
| Currency | EUR |
| 52 week range | 0.770 - 4.46 |
| Market Capitalization | 56.84M |
| P/E trailing | -3.95 |
| P/E forward | -4.19 |
| Price/Sale | 52.53 |
| Beta | 1.19 |
| EPS | -0.070 |
| EPS France (ID:70, base:331) | -1.54 |